Literature DB >> 8287610

Production and secretion of interferon-gamma (IFN-gamma) in children with atopic dermatitis.

M Tang1, A Kemp.   

Abstract

IFN-gamma is known to be a major inhibitor of IgE synthesis in vitro. Recent studies demonstrating reduced production of IFN-gamma in children and adults with atopic dermatitis and elevated serum IgE suggest a similar role for this cytokine in vivo. The reasons for this reduced IFN-gamma production are not known. One possibility is that atopic individuals have a reduced population of cells producing IFN-gamma in vivo. Using a fluorescence-labelled antibody to detect intracellular IFN-gamma, the percentage of IFN-gamma-producing cells was determined in children with atopic dermatitis and in non-atopic controls. Children with atopic dermatitis had a greater percentage of IFN-gamma-producing cells in unstimulated cultures compared with controls, indicating in vivo activation of lymphocytes in the atopic group. This could reflect the significant degree of inflammation present in these children, or the presence of bacterial infection or colonization. Although secretion of IFN-gamma after stimulation with phorbol myristate acetate (PMA)/Ca was significantly lower in children with atopic dermatitis compared with controls, the percentage of IFN-gamma-producing cells in the stimulated cultures from this group was equivalent to controls. This demonstrates that the reduced ability of atopic children to secrete IFN-gamma in vitro does not relate to a lack of IFN-gamma-producing cells, but to a difference in the regulation of IFN-gamma production beyond the stage of signal transduction.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8287610      PMCID: PMC1534643          DOI: 10.1111/j.1365-2249.1994.tb06016.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  37 in total

Review 1.  Assessment of cytokines by immunofluorescence and the paraformaldehyde-saponin procedure.

Authors:  B Sander; J Andersson; U Andersson
Journal:  Immunol Rev       Date:  1991-02       Impact factor: 12.988

2.  Functional characterization of skin-infiltrating lymphocytes in atopic dermatitis.

Authors:  U Reinhold; S Kukel; B Goeden; U Neumann; H W Kreysel
Journal:  Clin Exp Immunol       Date:  1991-12       Impact factor: 4.330

3.  Detection of intracellular expression and secretion of interferon-gamma at the single-cell level after activation of human T cells with tetanus toxoid in vitro.

Authors:  L Kabilan; G Andersson; F Lolli; H P Ekre; T Olsson; M Troye-Blomberg
Journal:  Eur J Immunol       Date:  1990-05       Impact factor: 5.532

4.  Defective in vitro production of gamma-interferon and tumor necrosis factor-alpha by circulating T cells from patients with the hyper-immunoglobulin E syndrome.

Authors:  G Del Prete; A Tiri; E Maggi; M De Carli; D Macchia; P Parronchi; M E Rossi; M C Pietrogrande; M Ricci; S Romagnani
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

5.  Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma.

Authors:  D S Robinson; Q Hamid; S Ying; A Tsicopoulos; J Barkans; A M Bentley; C Corrigan; S R Durham; A B Kay
Journal:  N Engl J Med       Date:  1992-01-30       Impact factor: 91.245

6.  T cell activation-inducing epitopes of the house dust mite allergen Der p I. Proliferation and lymphokine production patterns by Der p I-specific CD4+ T cell clones.

Authors:  H Yssel; K E Johnson; P V Schneider; J Wideman; A Terr; R Kastelein; J E De Vries
Journal:  J Immunol       Date:  1992-02-01       Impact factor: 5.422

7.  Modulation of IL-4-induced human IgE production in vitro by IFN-gamma and IL-5: the role of soluble CD23 (s-CD23).

Authors:  J Pène; I Chrétien; F Rousset; F Brière; J Y Bonnefoy; J E de Vries
Journal:  J Cell Biochem       Date:  1989-03       Impact factor: 4.429

8.  Allergen- and bacterial antigen-specific T-cell clones established from atopic donors show a different profile of cytokine production.

Authors:  P Parronchi; D Macchia; M P Piccinni; P Biswas; C Simonelli; E Maggi; M Ricci; A A Ansari; S Romagnani
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-15       Impact factor: 11.205

9.  Evidence for compartmentalization of functional subsets of CD2+ T lymphocytes in atopic patients.

Authors:  E A Wierenga; M Snoek; C de Groot; I Chrétien; J D Bos; H M Jansen; M L Kapsenberg
Journal:  J Immunol       Date:  1990-06-15       Impact factor: 5.422

10.  Induction of human IgE synthesis requires interleukin 4 and T/B cell interactions involving the T cell receptor/CD3 complex and MHC class II antigens.

Authors:  D Vercelli; H H Jabara; K Arai; R S Geha
Journal:  J Exp Med       Date:  1989-04-01       Impact factor: 14.307

View more
  5 in total

1.  Reduced production of both Th1 and Tc1 lymphocyte subsets in atopic dermatitis (AD).

Authors:  A Lonati; S Licenziati; A D Canaris; S Fiorentini; G Pasolini; M Marcelli; S Seidenari; A Caruso; G De Panfilis
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

2.  Increased secretion of IL-18 in vitro by peripheral blood mononuclear cells of patients with bronchial asthma and atopic dermatitis.

Authors:  R E El-Mezzein; T Matsumoto; H Nomiyama; T Miike
Journal:  Clin Exp Immunol       Date:  2001-11       Impact factor: 4.330

3.  Allergen-stimulated interleukin-4 and interferon-gamma production in primary culture: responses of subjects with allergic rhinitis and normal controls.

Authors:  M Imada; F E Simons; F T Jay; K T Hayglass
Journal:  Immunology       Date:  1995-07       Impact factor: 7.397

4.  Spontaneous expression of IL-4 mRNA in lymphocytes from children with atopic dermatitis.

Authors:  M L Tang; A S Kemp
Journal:  Clin Exp Immunol       Date:  1994-09       Impact factor: 4.330

5.  Reduced interferon-gamma (IFN-gamma) secretion with increased IFN-gamma mRNA expression in atopic dermatitis: evidence for a post-transcriptional defect.

Authors:  M L Tang; G Varigos; A S Kemp
Journal:  Clin Exp Immunol       Date:  1994-09       Impact factor: 4.330

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.